Publications by authors named "G J Gert-Jan Braunstahl"
Article Synopsis
- Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis (AD) and severe asthma (SA), but there hasn't been much real-world analysis on its adverse events, particularly those related to the eyes (DAOSD).
- This study analyzed data from patients with AD and SA receiving dupilumab to compare the prevalence of adverse events, focusing on ocular problems and treatment discontinuation rates.
- Results showed a higher prevalence of ocular adverse events in AD patients (62.1%), while SA patients experienced more headaches and injection site reactions, underlining the need for physician awareness when prescribing dupilumab to AD patients and emphasizing the effectiveness of ophthalmic treatments for managing eye-related issues.
Background: Long COVID is a heterogeneous condition with a variety of symptoms that persist at least 3 months after SARS-CoV-2 infection, often with a profound impact on quality of life. Lactoferrin is an iron-binding glycoprotein with anti-inflammatory and antiviral properties. Current hypotheses regarding long COVID aetiology include ongoing immune activation, viral persistence and auto-immune dysregulation.
View Article and Find Full Text PDFBackground: Severe asthma (SA) presents a considerable healthcare challenge despite optimal standard treatment. Dupilumab, which is effective in type 2 (T2) SA patients, demonstrates variable responses, categorizing patients as non-responders, partial responders, or those achieving clinical remission. However, real-world response rates remain underexplored.
View Article and Find Full Text PDF